| Name | Title | Contact Details |
|---|
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.
Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery.
Aderans Research is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.